Jim Ellis
Chief Scientific Officer Nocion Therapeutics, Inc.
Jim has been CSO at Nocion since July 2018. He has over 30 years leadership experience in drug discovery in multiple therapeutic areas, working in organizations from biotech startups to large pharma. Most recently, Jim lead GSK’s Innovation Hub in Cambridge after serving as Vice President and Head of GSK’s Sirtuin Discovery Performance Unit. Prior to GSK, Jim was Vice President of Research for Surface Logix and the Executive Project Director and Chief Biology Advisor for NitroMed. Previously, Jim was the Group Director, Allergy and Respiratory Disease and Senior Director of Pharmacology at UCB Pharma where he was responsible for UCB’s global allergy and respiratory franchise research pipeline. Prior to joining industry, Jim was an Assistant Professor of Medicine at Johns Hopkins University, where he also did his post-doctoral research. James received his B.Sc. in Pharmacology from the University of Aberdeen in Scotland and his Ph.D. in Neurobiology from University College London.
Seminars
- Selective local targeting of cough nociceptors to provide meaningful clinical outcomes in patients with refractory chronic cough
- Interpreting Phase 2b clinical data to understand exposure response relationships, tolerability & efficacy
- Achieving sufficient local exposure in lung tissue while avoiding systemic liability
- Human proof of concept for selective sodium channel blockade to de-risk respiratory ion channel development
- Discussing how programs evolved in response to clinical data and operational realities
- Sharing insights gained through adaptation, iteration, and risk management during development
- Informing future discovery and development choices with experience-based perspective
